Method Profile
Combine field-potential recording and microscopy on a transparent electrode surface to follow acute channel effects and longer cellular injury.
Characterize electrical, viability and structural responses during preclinical cardiac-safety studies.
Day-30 cardiomyocytes from one human BJ fibroblast-derived induced pluripotent stem cell line; 97.06% cardiac-troponin-T positivity and predominantly ventricular-associated marker staining.
CFPS-ITO-16W2E transparent 16-well/two-electrode-per-well array with CFPS-32 recording; calcium fluorescence, live/dead and α-actinin imaging.
Human cardiomyocytes
Single BJ-derived line; fibronectin-coated ITO surfaces with five to six days of stabilization before recording.
Drug comparisons
Stepwise acute E-4031 at 0.003–0.03 μM and nifedipine at 0.008–0.8 μM; separate 3 μM doxorubicin exposure followed for two days; 0.1% DMSO controls.
Compare acute concentration responses and separate day-zero/one/two doxorubicin recordings. Preserve raw and corrected duration when beat period changes markedly; reported error bars are SEM.
Opposing reference channel blockers and a separate sustained doxorubicin injury condition.
One stem-cell origin; baseline field-potential n = 12, calcium n = 3, drug electrophysiology n = 5; acute vehicle n = 4.
Pre-exposure recording and corresponding vehicle/time controls.
E-4031 prolonged corrected duration; nifedipine shortened it without significant amplitude change. Doxorubicin slowed beating and prolonged raw duration while corrected duration initially fell; viability and sarcomeric integrity deteriorated.
A transparent microelectrode chip recorded drug-induced electrical changes while allowing imaging of the same human stem-cell-derived cardiomyocytes. Acute channel blockade altered electrical activity with little visible damage, whereas two-day doxorubicin exposure disrupted cell structure and viability.
